Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir

A patient with genotype 1b chronic hepatitis C virus who had been treated with pegylated interferon and ribavirin (RBV) was treated with glecaprevir/pibrentasvir (GLE/PIB) for 12 weeks. A sustained virological response at post-treatment week 12 (SVR12) was achieved, but relapse occurred approximatel...

Descripción completa

Detalles Bibliográficos
Autores principales: Manabe, Takushi, Tadokoro, Tomoko, Nakahara, Mai, Ohura, Kyoko, Fujita, Koji, Tani, Joji, Morishita, Asahiro, Ogawa, Chikara, Masaki, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518557/
https://www.ncbi.nlm.nih.gov/pubmed/36450472
http://dx.doi.org/10.2169/internalmedicine.0865-22
_version_ 1785109540878942208
author Manabe, Takushi
Tadokoro, Tomoko
Nakahara, Mai
Ohura, Kyoko
Fujita, Koji
Tani, Joji
Morishita, Asahiro
Ogawa, Chikara
Masaki, Tsutomu
author_facet Manabe, Takushi
Tadokoro, Tomoko
Nakahara, Mai
Ohura, Kyoko
Fujita, Koji
Tani, Joji
Morishita, Asahiro
Ogawa, Chikara
Masaki, Tsutomu
author_sort Manabe, Takushi
collection PubMed
description A patient with genotype 1b chronic hepatitis C virus who had been treated with pegylated interferon and ribavirin (RBV) was treated with glecaprevir/pibrentasvir (GLE/PIB) for 12 weeks. A sustained virological response at post-treatment week 12 (SVR12) was achieved, but relapse occurred approximately 31 weeks after the end of treatment. The patient had a history of allergy to RBV and was treated with ledipasvir/sofosbuvir (LDV/SOF), achieving SVR12 and remaining hepatitis C virus-negative until 24 weeks after the completion of treatment. LDV/SOF can thus be a secondary treatment for GLE/PIB.
format Online
Article
Text
id pubmed-10518557
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-105185572023-09-26 Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir Manabe, Takushi Tadokoro, Tomoko Nakahara, Mai Ohura, Kyoko Fujita, Koji Tani, Joji Morishita, Asahiro Ogawa, Chikara Masaki, Tsutomu Intern Med Case Report A patient with genotype 1b chronic hepatitis C virus who had been treated with pegylated interferon and ribavirin (RBV) was treated with glecaprevir/pibrentasvir (GLE/PIB) for 12 weeks. A sustained virological response at post-treatment week 12 (SVR12) was achieved, but relapse occurred approximately 31 weeks after the end of treatment. The patient had a history of allergy to RBV and was treated with ledipasvir/sofosbuvir (LDV/SOF), achieving SVR12 and remaining hepatitis C virus-negative until 24 weeks after the completion of treatment. LDV/SOF can thus be a secondary treatment for GLE/PIB. The Japanese Society of Internal Medicine 2022-11-30 2023-09-01 /pmc/articles/PMC10518557/ /pubmed/36450472 http://dx.doi.org/10.2169/internalmedicine.0865-22 Text en Copyright © 2023 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Manabe, Takushi
Tadokoro, Tomoko
Nakahara, Mai
Ohura, Kyoko
Fujita, Koji
Tani, Joji
Morishita, Asahiro
Ogawa, Chikara
Masaki, Tsutomu
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
title Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
title_full Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
title_fullStr Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
title_full_unstemmed Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
title_short Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
title_sort ledipasvir/sofosbuvir is effective for relapsed genotype 1b hepatitis c virus patients after achieving a sustained virological response at post-treatment week 12 with glecaprevir/pibrentasvir
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518557/
https://www.ncbi.nlm.nih.gov/pubmed/36450472
http://dx.doi.org/10.2169/internalmedicine.0865-22
work_keys_str_mv AT manabetakushi ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir
AT tadokorotomoko ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir
AT nakaharamai ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir
AT ohurakyoko ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir
AT fujitakoji ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir
AT tanijoji ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir
AT morishitaasahiro ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir
AT ogawachikara ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir
AT masakitsutomu ledipasvirsofosbuviriseffectiveforrelapsedgenotype1bhepatitiscviruspatientsafterachievingasustainedvirologicalresponseatposttreatmentweek12withglecaprevirpibrentasvir

Ejemplares similares